Edition:
United Kingdom

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

5,519JPY
1:29am BST
Change (% chg)

¥50 (+0.91%)
Prev Close
¥5,469
Open
¥5,428
Day's High
¥5,521
Day's Low
¥5,426
Volume
222,900
Avg. Vol
2,036,161
52-wk High
¥5,820
52-wk Low
¥3,277

About

DAIICHI SANKYO COMPANY, LIMITED is a Japan-based holding company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the... (more)

Overall

Beta: 0.95
Market Cap(Mil.): ¥3,959,828.00
Shares Outstanding(Mil.): 709.01
Dividend: 35.00
Yield (%): 1.25

Financials

  4568.T Industry Sector
P/E (TTM): 38.82 54.03 55.51
EPS (TTM): 143.88 -- --
ROI: 5.75 11.89 11.59
ROE: 7.84 13.19 16.33

FDA advisory panel votes against Daiichi Sankyo's blood cancer treatment

Independent experts on an advisory panel to the U.S. Food and Drug Administration on Tuesday voted against Daiichi Sankyo Co Ltd's treatment for adults with a type of acute myeloid leukemia.

14 May 2019

UPDATE 1-FDA advisory panel votes against Daiichi Sankyo's blood cancer treatment

May 14 Independent experts on an advisory panel to the U.S. Food and Drug Administration on Tuesday voted against Daiichi Sankyo Co Ltd's treatment for adults with a type of acute myeloid leukemia.

14 May 2019

FDA advisory panel votes against Daiichi Sankyo's cancer treatment

May 14 Independent experts on an FDA advisory panel on Tuesday voted against Daiichi Sankyo Co Ltd's treatment for adults with a type of acute myeloid leukemia.

14 May 2019

AstraZeneca-Daiichi breast cancer treatment shows promise in latest study

An experimental breast cancer drug being developed by British drugmaker AstraZeneca and Japan's Daiichi Sankyo's met its main goal in a mid-stage study, bolstering their position in a highly competitive oncology market.

08 May 2019

AstraZeneca-Daiichi Sankyo breast cancer drug shows promise

May 8 British drugmaker AstraZeneca and Japan's Daiichi Sankyo said on Wednesday their experimental treatment for breast cancer met its key goal in a mid-stage study, bolstering their defences in a highly competitive oncology market.

08 May 2019

AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal

AstraZeneca Plc will pay up to $6.9 billion to work with Daiichi Sankyo Co Ltd on a hotly-tipped experimental treatment for breast cancer, in a direct challenge to the world's biggest cancer drug maker Roche.

29 Mar 2019

AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal

AstraZeneca Plc will pay up to $6.9 billion (5.2 billion pounds) to work with Daiichi Sankyo Co Ltd on a hotly-tipped experimental treatment for breast cancer, in a direct challenge to the world's biggest cancer drug maker Roche.

29 Mar 2019

UPDATE 5-AstraZeneca pays up to $6.9 bln in Daiichi Sankyo cancer deal

* Astra stock slides, deal part-funded by share issue (Releads, adds details on rivalry, analyst comments)

29 Mar 2019

Nikkei up on U.S.-China trade talk optimism; Daiichi Sankyo jumps

TOKYO, March 29 Japan's Nikkei rose on Friday on optimism about the latest round of U.S.-China trade talks, with cyclical sectors such as shipping and machinery advancing on the last day of the Japanese fiscal year.

29 Mar 2019

REFILE-Nikkei rises on optimism over U.S.-China trade talks; Daiichi Sankyo jumps

* Nikkei has shed 2.1 for week, dropped 1 pct for month so far

29 Mar 2019

Earnings vs. Estimates